Benjamin Cornell Psychologist Medicare: Not Enrolled in Medicare Practice Location: 31946 Mission Trail, Suite B, Lake Elsinore, CA 92530 Phone: 951-245-7663 |
Dr. Michael E Geraghty, PH.D. Psychologist - Clinical Medicare: Accepting Medicare Assignments Practice Location: 35620 Desert Rose Way, Lake Elsinore, CA 92532 Phone: 951-409-1750 |
Miss Lourdes Patricia Gabucan, AMFT Psychologist - Clinical Medicare: Not Enrolled in Medicare Practice Location: 265 San Jacinto River Rd, Lake Elsinore, CA 92530 Phone: 951-291-4336 |
Julia Mae Miller, PPS Psychologist - School Medicare: Not Enrolled in Medicare Practice Location: 34133 Dianthus Ln, Lake Elsinore, CA 92532 Phone: 661-583-2493 |
Dr. Stephanie Ann Peoples, PSY.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 31946 Mission Trail, Suite B, Lake Elsinore, CA 92530 Phone: 951-245-7663 Fax: 951-674-6431 |
Dr. Donna Evelyn, PH.D. Psychologist - Clinical Medicare: Not Enrolled in Medicare Practice Location: 31946 Mission Trl, Ste B, Lake Elsinore, CA 92530 Phone: 951-245-7663 Fax: 951-674-6431 |
News Archive
Why do some people develop post-traumatic stress disorder (PTSD) while others who suffered the same ordeal do not? A new UCLA discovery may shed light on the answer.
Neurowave Medical Technologies™ today announced the release of an innovative new device for the treatment of post-operative nausea, medically referred to as emesis. Reletex™ is a novel transdermal neuromodulation device that is non-invasive and drug-free, and has been demonstrated to alleviate nausea when used as an adjunct to anti-emetics.
This Friday, September 18th at 9:50 am, FRC Action will host a Congressional townhall panel that will discuss the economic and moral implications of health care reform. The panel will be a part of the fourth annual Values Voter Summit and will feature Congressman Tom Price (R-GA), Congresswoman Michele Bachmann (R-MN), and Congressman Chris Smith (R-NJ). The panel will also take questions from the audience.
CureFAKtor Pharmaceuticals, LLC, a privately-held biopharmaceutical company focused on the research and development of Focal Adhesion Kinase (FAK) inhibitors for cancer, today presented research results at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco demonstrating that novel FAK inhibitors targeting the binding site of vascular endothelial growth factor receptor 3 (VEGFR-3) reduced the growth of pancreatic cancer cells in vitro and in vivo.
An international team of researchers led by a University of Virginia School of Medicine professor is warning that scientists must better prepare for the next pandemic - and has developed a plan to do just that.
› Verified 1 days ago